FLU SV MRNA-002

Research into a new vaccine that works against multiple flu viruses

About the clinical trial

The FLU SV MRNA-002 study is a clinical trial by GlaxoSmithKline Biologicals S.A., in which the ITM Clinical Trial Site participated. The purpose of the trial was to evaluate a new influenza vaccine designed to protect against multiple influenza viruses. It assessed both the safety of the vaccine and the human body's response to it.

The study ran from November 2023 to June 2024, and 43 healthy adult subjects participated. Participants were administered either the study vaccine or an existing vaccine once, and were then followed up for six months. For more scientific background on the trial, please visit the database where trials must be officially registered.

Team

Principal investigator ITM: Prof Dr Patrick Soentjens (MD, PhD)

Registration closed

We are no longer accepting participants for this trial, but there may be other trials ongoing for which you can register. An overview can be found here. Would you like to stay informed about upcoming trials? Be sure to sign up for our mailing list.

Share this trial on